Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
mCRPC (Metastatic Castration-resistant Prostate Cancer): early-phase trial registry
6 of 6 indexed mCRPC (Metastatic Castration-resistant Prostate Cancer) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 6 currently recruiting · #2,866 of 28,707 conditions by registered trial count
mCRPC (Metastatic Castration-resistant Prostate Cancer): 6 US clinical trials tracked, 6 recruiting.
mCRPC (Metastatic Castration-resistant Prostate Cancer) is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Orano Med, running 1 of these trials.
Enrollment posture brief
Registry condition mcrpc-metastatic-castration-resistant-prostate-cancer
OPEN 6 | RECR 100% | LATE 0 | EARLY 6 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
mCRPC (Metastatic Castration-resistant Prostate Cancer) lists 6 open slots (100% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for mCRPC (Metastatic Castration-resistant Prostate Cancer) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
mCRPC (Metastatic Castration-resistant Prostate Cancer) is recruiting above its size-band peers.
6 of 6 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates mCRPC (Metastatic Castration-resistant Prostate Cancer) research.
Orano Med accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical mCRPC (Metastatic Castration-resistant Prostate Cancer) enrolment sits around 126 participants.
Median target enrolment is 126 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.
-
mCRPC (Metastatic Castration-resistant Prostate Cancer) research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Pathos AI
NCT06785636
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
K36 Therapeutics
NCT07103018
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer Clinical Trials Consortium
NCT06844383
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Acerand Therapeutics (Hong Kong) Limited
NCT06801236
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity
NCT06190899
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med
NCT05283330
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on mCRPC (Metastatic Castration-resistant Prostate Cancer) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on mCRPC (Metastatic Castration-resistant Prostate Cancer) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this mCRPC (Metastatic Castration-resistant Prostate Cancer) page
6 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 mCRPC (Metastatic Castration-resistant Prostate Cancer) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Orano Med sponsors the most mCRPC (Metastatic Castration-resistant Prostate Cancer) trials on record, review their full trial history before evaluating a specific study. See Orano Med's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This mCRPC (Metastatic Castration-resistant Prostate Cancer) condition card totals 6 registered trials; most-linked intervention Talazoparib with enzalutamide; top US site state Nebraska. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.